Compugen to Present Immune Checkpoint Related Research at Two Scientific Conferences
July 24 2014 - 7:00AM
Business Wire
Utilization of predictive discovery to
identify 11 novel checkpoint molecules to be presented at
Immunotherapies and Vaccines Summit in Boston
Results for CGEN-15001 fusion protein based
on checkpoint protein candidate to be presented at International
Conference on Immune Tolerance in Amsterdam
Compugen Ltd. (NASDAQ: CGEN) today announced that it will
present aspects of its immune checkpoint related research at two
upcoming scientific conferences. On August 11, John Hunter, PhD,
Site Head & Vice President, Antibody Research & Development
at Compugen USA, Inc., will present at the Immunotherapies and
Vaccines Summit (ImVacs) being held from August 11-14, in Boston,
MA. In his talk, which is scheduled as part of the Immunomodulatory
Therapeutic Antibodies for Cancer: Discovery and Development of the
Next Wave of Checkpoint Inhibitors track, Dr. Hunter will discuss
how Compugen has utilized its predictive discovery platforms to
identify 11 novel immune checkpoints which potentially can serve as
targets for antibody immunotherapy in cancer. Dr. Hunter will
present validation data for two of these targets, CGEN-15049 and
CGEN-15052.
The Company will also present at the 3rd International
Conference on Immune Tolerance 2014, from September 28-30, 2014 in
Amsterdam, The Netherlands. In a talk titled, CGEN-15001, a novel
immune-modulatory Fc fusion protein is efficacious in models of
autoimmune diseases and induces immune tolerance, Iris
Hecht, PhD, Principal Scientist at Compugen, will review
results for CGEN-15001, a fusion protein based on another immune
checkpoint candidate discovered by the Company. Dr. Hecht will
present results demonstrating long lasting efficacy in animal
models of several autoimmune diseases as well as data supporting
potential restoration of immune tolerance by CGEN-15001. Immune
tolerance induction is a highly sought-after approach for treatment
of autoimmune diseases such as rheumatoid arthritis, multiple
sclerosis and type 1 diabetes.
Also at the Amsterdam conference, CGEN-15001 will be the subject
of a poster presentation by Joseph R. Podojil, PhD, from the
laboratory of Stephen Miller, Judy Gugenheim Research Professor of
Microbiology-Immunology at Northwestern University Feinberg School
of Medicine. In his presentation, titled Tolerogenic and
immunomodulatory effects in the EAE model of multiple sclerosis
induced by CGEN-15001, an Fc- fused protein derived from a novel
immune checkpoint, Dr. Podojil will present data on the cellular
mechanism underlying restoration of immune balance and induction of
immune tolerance by CGEN-15001, suggesting that CGEN-15001 is a
promising drug candidate for the treatment of autoimmune
diseases.
About Compugen
Compugen is a leading drug discovery company focused on
therapeutic proteins and monoclonal antibodies to address important
unmet needs in the fields of immunology and oncology. The
Company utilizes a broad and continuously growing integrated
infrastructure of proprietary scientific understandings and
predictive platforms, algorithms, machine learning systems and
other computational biology capabilities for the in
silico (by computer) prediction and selection of product
candidates, which are then advanced in its Pipeline Program. The
Company's business model includes collaborations covering the
further development and commercialization of product candidates at
various stages from its Pipeline Program and various forms of
research and discovery agreements, in both cases providing Compugen
with potential milestone payments and royalties on product sales or
other forms of revenue sharing. Compugen’s wholly-owned U.S.
subsidiary located in South San Francisco is developing oncology
and immunology monoclonal antibody therapeutic candidates against
its drug targets. For additional information, please visit
Compugen's corporate website at www.cgen.com.
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements, include words such as “may,” “expects,”
“anticipates,” “potential,” “believes,” and “intends,” and describe
opinions about future events. Forward-looking statements in this
press release include, but are not limited to, statements relating
to the potential use of Compugen discovered checkpoint molecules as
targets for antibody immunotherapy in cancer, and of CGEN-15001 as
a drug candidate for the treatment of autoimmune and inflammatory
diseases. These forward-looking statements involve known and
unknown risks and uncertainties that may cause the actual results,
performance or achievements of Compugen to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. These and other risks
are discussed in the "Risk Factors" section of Compugen’s most
recent Annual Report on Form 20-F as filed with the Securities and
Exchange Commission as well as other documents that may be
subsequently filed by Compugen from time to time with the
Securities and Exchange Commission. In addition, any
forward-looking statements represent Compugen’s views only as of
the date of this release and should not be relied upon as
representing its views as of any subsequent date. Compugen does not
assume any obligation to update any forward-looking statements
unless required by law.
Compugen Ltd.Tsipi HaitovskyGlobal Media
Liaison+972-52-598-9892tsipih@cgen.com
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024